Sector News

NPS Pharma asks Goldman Sachs to find a buyer: WSJ

January 6, 2015
Life sciences
Long cited as a takeover target, rare disease specialist NPS Pharmaceuticals is seeking a buyer, according to a report in the Wall Street Journal.
 
The newspaper reports that Goldman Sachs has started to contact companies to gauge their interest in NPS, which may be available at upwards of $4.5 billion. Shire has regularly been mentioned as a potential purchaser and is on the look-out for acquisitions having had its warchest boosted by a $1.6 billion break-up fee banked after AbbVie pulled out of a proposed merger last year.
 
NPS currently markets Gattex/Revestive (teduglutide) for short bowel syndrome. It is also waiting to hear from the US Food and Administration about Natpara (recombinant human parathyroid hormone) for the treatment of hypoparathyroidism and a decision is expected by the end of this month.
 
By Kevin Grogan
 
Source: Pharma Times
 

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.